C. Folens

发表

Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.

P. Marynen, M. Fornerod, D. Gilliland, 2008, Molecular cell.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

P. Marynen, J. Cools, N. Mentens, 2006, Blood.

Sorafenib (BAY43-9006) is a potent inhibitor of FIP1L1-PDGFR α and the imatinib resistant FIP1L1-PDGFR α T674I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome

P. Marynen, C. Mecucci, M. Martelli, 2007, Leukemia.

Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate

P. Marynen, R. Sciot, M. Debiec‐Rychter, 2006, Clinical Cancer Research.

Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

P. Marynen, D. Gilliland, J. Cools, 2006 .

Activation of FIP 1 L 1-PDGFR requires disruption of the juxtamembrane domain of PDGFR and is FIP 1 L 1-independent

P. Marynen, D. Gilliland, J. Cools, 2006 .

In vitro validation of gamma-secretase inhibitors for the treatment of T-cell acute lymphoblastic leukemia

P. Marynen, I. Lahortiga, J. Cools, 2007 .

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

P. Marynen, D. Gilliland, J. Cools, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

Sorafenib is a potent inhibitor of FIP 1 L 1-PDGFR and the imatinib-resistant FIP 1 L 1-PDGFR T 674 I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

P. Marynen, M. Odero, L. van Neste, 2008, Haematologica.